CD134 Antibody: How can Reshaping T Cell Function Revolutionize Immunotherapy?

1. What are the biological characteristics and immunomodulatory functions of CD134?
CD134, also known as tumor necrosis factor receptor superfamily member 4, is an important immune co-stimulatory molecule. This molecule is primarily induced and expressed after T cell activation, and through interaction with its ligand CD134L, it plays multiple regulatory roles in immune responses. Mechanistically, the CD134 signaling pathway can effectively balance the inhibitory states of CD4+ and CD8+ T lymphocytes, directly stimulate the activation and proliferation of effector T cells, while also modulating the functions of natural killer cells and B lymphocytes. Notably, CD134 binding to its ligand promotes the secretion of interleukin-4 and interleukin-13, and by influencing the functional state of regulatory T cells, it alters the immunosuppressive characteristics of the immune microenvironment.
 

 
2. What are the classification and mechanism of action characteristics of CD134-targeted drugs?
Based on the dual roles of CD134 in immunomodulation, targeted drugs for this molecule are mainly divided into two categories: agonistic antibodies and antagonistic antibodies. Agonistic antibodies mimic the function of natural ligands, enhancing co-stimulatory signals, promoting the activation of effector T cell populations, and reversing regulatory T cell-mediated immune suppression. These drugs are primarily used in the treatment of advanced tumors. Conversely, antagonistic antibodies block the CD134 signaling pathway, inhibiting the function of Th2-related T cells, and are mainly targeted at autoimmune diseases. This bidirectional regulatory capability makes CD134 a highly promising target in the field of immunotherapy.

3. What is the clinical research progress of CD134 agonistic antibodies?
Currently, CD134 agonistic antibodies show broad prospects in the field of tumor immunotherapy. Multiple clinical studies are exploring their use as monotherapy or in combination with immune checkpoint inhibitors. Preliminary research data indicate that these drugs can effectively enhance the anti-tumor activity of T cells and improve the immunosuppressive state of the tumor microenvironment. In terms of drug design, researchers are optimizing antibody affinity, specificity, and Fc segment functionality to achieve the best balance between efficacy and safety. Although all candidate drugs are still in the clinical research stage, existing evidence supports the potential value of CD134 agonistic antibodies in tumor treatment.

4. What are the clinical application prospects of CD134 antagonistic antibodies?
In the field of autoimmune diseases, CD134 antagonistic antibodies specifically block co-stimulatory signals, inhibiting abnormally activated immune responses. These drugs primarily target autoimmune pathological processes driven by excessive activation of Th2 cells.
Preclinical studies show that blocking CD134 signaling can effectively reduce inflammatory responses and tissue damage, providing new insights for the treatment of autoimmune diseases. Currently, related candidate drugs have entered the clinical research stage, and initial results will provide important references for the clinical application of these drugs.

5. What is the positioning of CD134 in the immune checkpoint network?
In the complex immunoregulatory network, CD134 belongs to the category of co-stimulatory molecules, forming a delicate immune balance system together with co-inhibitory molecules such as cytotoxic T-lymphocyte-associated protein 4 and programmed death receptor 1. Complete activation of T cells requires simultaneous reception of T cell receptor signals and co-stimulatory signals, and CD134 plays a key role in this process. Unlike traditional immune checkpoint inhibitors, CD134 agonists positively regulate immune responses, providing a complementary strategy for tumor immunotherapy. This bidirectional regulatory characteristic makes CD134 an important node connecting co-inhibitory and co-stimulatory signals.

6. What are the future development directions for CD134-targeted therapy?
With the deepening understanding of CD134's biological functions, the therapeutic development of this target is showing a trend of diversification. At the technical level, the development of bispecific antibodies combining CD134 with other immune targets may produce synergistic effects. In terms of application strategies, exploring optimal combinations of CD134-targeted drugs with traditional chemotherapy, radiotherapy, and other immunotherapies has become an important direction. Additionally, biomarker-based patient stratification and personalized treatment strategies will improve the precision of CD134-targeted therapy. Future research also needs to further clarify the dynamic changes of CD134 in different disease stages and immune environments to provide more comprehensive guidance for clinical medication.

7. Conclusion
As an important immune co-stimulatory molecule, CD134 plays a central role in immune responses by regulating T cell function. Agonistic and antagonistic antibodies targeting this molecule provide new approaches for the treatment of tumors and autoimmune diseases, respectively. With the continuous advancement of clinical research and the emergence of technological innovations, CD134-targeted therapy is expected to play an increasingly important role in the field of immunotherapy, offering new treatment options for more patients.

8. Which manufacturers provide CD134 antibodies?
Hangzhou Start Biotech Co., Ltd. has independently developed the "Mouse Anti-Human CD134 Antibody" (product name: Mouse Anti-Human CD134 Antibody (S-R589), catalog number: S0B5119), a highly specific, excellent-affinity, and exceptionally stable detection tool for T cell co-stimulatory receptors. This product can accurately recognize human CD134 (OX40) protein and has important application value in T cell activation research, tumor immunotherapy, and autoimmune disease mechanism exploration.

 
Professional Technical Support: We provide detailed product technical documentation, including complete specificity validation data, application protocols, and professional technical support, fully assisting customers in making progress in T cell immunity and tumor immunotherapy research.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions to global innovative pharmaceutical companies and research institutions. For more details about the "Mouse Anti-Human CD134 Antibody" (catalog number S0B5119) or to request sample testing, please feel free to contact us.

Product Information

S0B5196	APC Mouse Anti-Human CD134 Antibody (S-R589)	Host : Mouse Conjugation : APC
S0B5112	FITC Mouse Anti-Human CD134 Antibody (S-R589)	Host : Mouse Conjugation : FITC
S0B5119	Mouse Anti-Human CD134 Antibody (S-R589)	Host : Mouse Conjugation : Unconjugated
S0B5237	Rat Anti-Mouse CD134 Antibody (S-R711)	Host : Rat Conjugation : Unconjugated